Curr Gastroenterol Rep (2011) 13:525–531 34. Gisbert JP, Khorrami S, Carballo F, et al. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non- eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther. 2004;19:617–29. 35. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo- oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double- blind, randomised trial. Lancet. 2007;369:1621–6. 36. van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26:265–75. 37. van Soest EM, Valkhoff VE, Mazzaglia G, et al.: Suboptimal gastroprotective coverage of NSAID use and the risk of upper 531 gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011, In press 38. Sung JJ, Lau JY, Ching JY, et al.: Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009, 152:1–9. This randomized study showed that patients taking aspirin for secondary prevention of cardiovascular disease, benefit from early restart of antiplatelet therapy after peptic ulcer bleeding in terms of all-case and cardiovascular- related mortality, at the expense of a limited increase of rebleeding without fatalities. 39. Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology. 2009;137:525–31.